Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus
NCT05669599 on ClinicalTrials.gov · last registry update 2026-01-20
An unusually large phase 2: 592 participants, more than double the 110 typical for the stage. The sponsor logged completion for 8 October 2024. Primary outcome, as filed: Percent Change From Baseline to Week 52 in Body Weight. maridebart cafraglutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Sponsor
- Amgen
- Sponsor type
- Industry
- Enrollment
- 592
- Started
- 2023-01-18
- Primary completion
- 2024-10-08 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percent Change From Baseline to Week 52 in Body Weight
Conditions studied
Obesity · Overweight · Type 2 Diabetes Mellitus
Every field above is taken directly from the registry record. See all detected changes across the class, or the maridebart cafraglutide page for this molecule’s full trial and approval history.